Multiple Sclerosis Clinical Trial
— MSOfficial title:
Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis
NCT number | NCT03536299 |
Other study ID # | 20068 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 31, 2018 |
Est. completion date | May 31, 2020 |
The purpose of this study is to determine the utility of a performance measure for the dual-task of gait and considering people with multiple sclerosis have both cognitive and motor problems, the secondary aim of this study is to determine the effectiveness of a gait-specific dual-tasking intervention for ambulatory individuals with multiple sclerosis.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | May 31, 2020 |
Est. primary completion date | May 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Ability walk independently with or without an assistive device - Independent and community-dwelling - No history or presence of other clinically significant musculoskeletal, cardiovascular, respiratory, or neurologic disease. - Definite diagnosis of MS [Expanded Disability Status Scale (EDSS) =6.5] - Relapse free for the past 30 days and not currently receiving or will receive any rehabilitation services during the study. Exclusion Criteria: - Participants experiencing a true relapse or exacerbation of their symptoms (>24 hours duration in the absence infection or fever, or and ambient increase in body temperature) during the study will be excluded from the study. |
Country | Name | City | State |
---|---|---|---|
United States | Texas Woman's University Institute of Health Sciences - Houston Center | Houston | Texas |
United States | TIRR Memorial Hermann Adult and Pediatric Outpatient Rehabilitation at the Kirby Glen Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
Texas Woman's University | The University of Texas Health Science Center, Houston, TIRR Memorial Hermann |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in Visual Analog Scale for Fatigue | The visual analog scale for fatigue measures immediate self-reported fatigue. This scale is commonly used to monitor and individual's fatigue level to ensure his or her safety during an activity. The individual marks his or her fatigue level on a 10-cm line with one end denoting "no fatigue" and the opposite end denoting "very severe fatigue". The individual's fatigue level is them measured in cm. | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Other | Changes in Borg Rating of Perceived Exertion | The Borg Rating of Perceived Exertion is a self-reported scale that measures how much exertion an individual is putting forth during a physical activity. It ranges from 6 (no exertion) to 20 (maximal exertion). The individual chooses a number between 6 and 20 to represent his or her level of exertion. This is commonly used to monitor an individual to ensure that he or she is exercising or performing within a safe level. | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Primary | Change in Walking and Remembering Test | Measures dual-task cost of gait and a titrated forward digit span cognitive task, measured as a percentage. | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Secondary | Change in 2-Minute Walk Test | Measures total distance walked by an individual within a 2-minute time period. Measures distance in feet and meters. | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Secondary | Change in 12-Item Multiple Sclerosis Walking Scale | Measures self-reported and self-perceived walking disability due to MS in the past 2 weeks. The 12-Item Multiple Sclerosis Walking Scale consists of 12 questions. Each question is rated on a Likert scale from 1 (not at all) to 5 (extremely). The items are scored for a minimum score possible of 12 or a maximal score of 60. This summed score is then divided by 60 and the resulting percentage is interpreted. The scale's final percentage score can range from a minimum of 20% (minimal impact of MS on walking, good outcome) to a maximum of 100% (significant impact of MS on walking, poor outcome). | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Secondary | Change in Fatigue Scale for Motor and Cognitive Functions | Measures self-reported physical and mental fatigue levels by the patient with MS. The Fatigue Scale for Motor and Cognitive Functions measures both the motor and cognitive domains of fatigue. The scale consists of 20 total items: 10 items related to motor fatigue and 10 items related to cognitive fatigue. Each item is rated on a Likert scale from 1 (does not apply at all) to 5 (applies completely). The scale items can be summed for a total score (ranging from 20 to 100) or subscales can be summed and interpreted with each subscale ranging from a minimum of 10 points to a maximal 50 points. Higher values in the total score or in the subscale scores indicate worse fatigue and poorer quality of life due to fatigue. | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Secondary | Change in Gait Speed | Changes in gait speed (m/s) will be measured for a 10-meter distance. This will be measured by the Protokinetics ZenoWalkway. | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Secondary | Change in Gait Cadence | Changes in gait cadence (steps/min) will be measured for a 10-meter distance. This will be measured by the Protokinetics ZenoWalkway. | Week 1, Week 2, Week 5, Week 8, Week 12 | |
Secondary | Change in Step Length | Changes in step length (cm) will be measured for a 10-meter distance. This will be measured by the Protokinetics ZenoWalkway. | Week 1, Week 2, Week 5, Week 8, Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |